Unknown

Dataset Information

0

Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.


ABSTRACT: The fusion oncoprotein Bcr-Abl is an aberrant tyrosine kinase responsible for chronic myeloid leukemia and acute lymphoblastic leukemia. The auto-inhibition regulatory module observed in the progenitor kinase c-Abl is lost in the aberrant Bcr-Abl, because of the lack of the N-myristoylated cap able to bind the myristoyl binding pocket also conserved in the Bcr-Abl kinase domain. A way to overcome the occurrence of resistance phenomena frequently observed for Bcr-Abl orthosteric drugs is the rational design of allosteric ligands approaching the so-called myristoyl binding pocket. The discovery of these allosteric inhibitors although very difficult and extremely challenging, represents a valuable option to minimize drug resistance, mostly due to the occurrence of mutations more frequently affecting orthosteric pockets, and to enhance target selectivity with lower off-target effects. In this perspective, we will elucidate at a molecular level the structural bases behind the Bcr-Abl allosteric control and will show how artificial intelligence can be effective to drive the automated de novo design towards off-patent regions of the chemical space.

SUBMITTER: Carofiglio F 

PROVIDER: S-EPMC7570842 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.

Carofiglio Francesca F   Trisciuzzi Daniela D   Gambacorta Nicola N   Leonetti Francesco F   Stefanachi Angela A   Nicolotti Orazio O  

Molecules (Basel, Switzerland) 20200914 18


The fusion oncoprotein Bcr-Abl is an aberrant tyrosine kinase responsible for chronic myeloid leukemia and acute lymphoblastic leukemia. The auto-inhibition regulatory module observed in the progenitor kinase c-Abl is lost in the aberrant Bcr-Abl, because of the lack of the <i>N</i>-myristoylated cap able to bind the myristoyl binding pocket also conserved in the Bcr-Abl kinase domain. A way to overcome the occurrence of resistance phenomena frequently observed for Bcr-Abl orthosteric drugs is t  ...[more]

Similar Datasets

| S-EPMC2951064 | biostudies-literature
| S-EPMC2901986 | biostudies-literature
| S-EPMC3517953 | biostudies-literature
| S-EPMC2901992 | biostudies-literature
2006-03-31 | GSE2810 | GEO
| S-EPMC4613337 | biostudies-literature
| S-EPMC4861451 | biostudies-literature
| S-EPMC7352889 | biostudies-literature
| S-EPMC5546432 | biostudies-literature
| S-EPMC1482597 | biostudies-literature